Lesson plan
RE245
RE245, or RE-245, is a non-hallucinogenic psychoplastogen which is under development for the treatment of psychiatric disorders. It is taken orally. The drug acts as a serotonin receptor modulator, including of the serotonin 5-HT 2A receptor, and is said to have psychoplastogenic effects. It is being developed by Reunion Neuroscience. As of August 2025, RE245 is in the preclinical research stage of development. An Investigational New Drug (IND) application to allow for phase 1 clinical trials is planned to be submitted in 2026, with these studies expected to start in 2027. The chemical structure of RE245 does not yet appear to have been disclosed.
Article summary
RE245, or RE-245, is a non-hallucinogenic psychoplastogen which is under development for the treatment of psychiatric disorders. It is taken orally. The drug acts as a serotonin receptor modulator, including of the serotonin 5-HT 2A receptor, and is said to have psychoplastogenic effects. It is being developed by Reunion Neuroscience. As of August 2025, RE245 is in the preclinical research stage of development. An Investigational New Drug (IND) application to allow for phase 1 clinical trials is planned to be submitted in 2026, with these studies expected to start in 2027. The chemical structure of RE245 does not yet appear to have been disclosed.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.